Results 1 to 10 of about 13,315,815 (204)

A homozygous CTLA-4 variant causes CTLA-4 deficiency with severe immune dysregulationNovel homozygous CTLA-4 variant in immune dysregulation [PDF]

Journal of Human Immunity
Catak et al. describe the first case of homozygous CTLA-4 deficiency, which drives severe early-onset autoimmunity through profound T and B cell dysregulation.
Mehmet Cihangir Catak, Salim Can, Satanay Hubrack, Feyza Bayram Catak, Asha Elmi, Royala Babayeva, Razin Amirov, Melek Yorgun Altunbas, Sevgi Bilgic Eltan, Deniz Ertem, Baris Yilmaz, Ahmet Koc, Batu Erman, Emine Bozkurtlar, Elif Karakoc-Aydiner, Ahmet Ozen, Bernice Lo, Safa Baris   +17 more
doaj   +2 more sources

Autosomal recessive human CTLA-4 deficiency with autoimmune infiltrationHuman CTLA-4 deficiency [PDF]

Journal of Human Immunity
A report in this issue of JHI deepens our understanding of human disease associated with loss of CTLA-4.
Helen C. Su
doaj   +2 more sources

CTLA-4: a moving target in immunotherapy [PDF]

Blood, 2017
CD28 and CTLA-4 are members of a family of Immunoglobulin-related receptors that are responsible for various aspects of T cell immune regulation. The family includes CD28, CTLA-4 and ICOS as well as other proteins including PD-1, BTLA and TIGIT.
Behzad Rowshanravan, Neil Halliday, D. Sansom   +2 more
semanticscholar   +4 more sources

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

Cell, 2016
SUMMARY Antibody blockade of the inhibitory CTLA-4 pathway has led to clinical benefit in a subset of patients with metastatic melanoma. Anti-CTLA-4 enhances T cell responses, including production of IFN-γ, which is a critical cytokine for host immune ...
Jianjun Gao, Lewis Zhichang Shi, Jianfeng Chen   +2 more
exaly   +2 more sources

DNA-PKcs orchestrates CTLA-4 depletion-induced senescence in cancer cells [PDF]

Cell Death and Disease
Immune checkpoints such as cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), programmed cell death 1 (PD-1), and programmed cell death ligand 1 (PD-L1) have been targeted in cancer therapy, however, the efficacy of these interventions remains limited.
Je-Jung Lee, Woo Joong Rhee, So Young Kim, Jisun Lee, Su Ful Jung, Jooyeon Oh, In Ho Park, Jeon-Soo Shin   +7 more
doaj   +2 more sources

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

Cell, 2017
Summary Immune checkpoint blockade is able to achieve durable responses in a subset of patients, however we lack a satisfying comprehension of the underlying mechanisms of anti-CTLA-4 and anti-PD-1 induced tumor rejection.
Spencer C Wei, Alexandria P Cogdill, Yang Zhao   +2 more
exaly   +2 more sources

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

Journal of Experimental & Clinical Cancer Research, 2021
The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1 (PD-1)/ programmed cell death-ligand 1 (PD-L1) are two most representative immune checkpoint pathways, which negatively regulate T cell immune function during different ...
Hao Zhang, Ziyu Dai, Wantao Wu, Zeyu Wang, Nan Zhang, Liyang Zhang, Wen-Jing Zeng, Zhixiong Liu, Quan Cheng   +8 more
doaj   +2 more sources

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

Cancer Cell, 2019
Cancer immunotherapies provide survival benefits in responding patients, but many patients fail to respond. Identifying the biology of treatment response and resistance are a priority to optimize drug selection and improve patient outcomes.
Tuba N Gide, Camelia Quek, Alexander M Menzies   +2 more
exaly   +2 more sources

Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy

Cancer Cell, 2022
Recruitment of lymphocytes into tumors is critical for anti-tumor immunity and efficacious immunotherapy. We show in murine models that tumor-associated high endothelial venules (TA-HEVs) are major sites of lymphocyte entry into tumors at baseline and ...
Robin Laffont, Severine Roy, Isabelle Girault   +2 more
exaly   +2 more sources

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

Cancer Cell, 2018
Summary With the use of a mouse model expressing human Fc-gamma receptors (FcγRs), we demonstrated that antibodies with isotypes equivalent to ipilimumab and tremelimumab mediate intra-tumoral regulatory T (Treg) cell depletion in vivo, increasing the ...
Frederick Arce Vargas, Andrew J S Furness, Kevin Litchfield   +2 more
exaly   +2 more sources